Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Annexon, Inc. is active in the Biotechnology & Pharmaceuticals technology area with 3 pending office actions. These 3 pending office actions are distributed across 2 distinct art units, indicating a slightly diversified technical focus within the biotechnology sector. For practitioners, the presence of 3 pending office actions in 2 distinct art units means that while some technical overlap may exist, the portfolio is subject to the examination standards of multiple specialized groups. Understanding the specific precedents within these 2 distinct art units is essential for a successful outcome.
The prosecution involves 3 distinct examiners, which means that every pending matter is being reviewed by a different official. ABBAS, SYED JARAR is identified as the busiest examiner, currently handling 1 pending office action. With 3 distinct examiners managing the 3 pending office actions, there is no centralization of the examination process at the individual level. This fragmentation requires practitioners to tailor their advocacy to different sets of examiner preferences and backgrounds. Successfully navigating the 3 pending office actions will depend on the ability to manage these diverse interactions while addressing the 1 pending office action assigned to the busiest examiner.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (67%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABBAS, SYED JARAR | 1 | 25.0% | +0.0% |
| DAHLE, CHUN WU | 1 | 50.2% | +51.1% |
| TAYLOR, LIA ELAN | 1 | 64.2% | +29.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18265380 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | ABBAS, SYED JARAR | 44d overdue |
| 17769180 | COMPOSITIONS AND METHODS FOR TREATING BLOOD DISORDERS | TAYLOR, LIA ELAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18100885 | HUMANIZED ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF | DAHLE, CHUN WU | 15d |
| 17769180 | COMPOSITIONS AND METHODS FOR TREATING BLOOD DISORDERS | TAYLOR, LIA ELAN | — |
| Art Unit | Apps |
|---|---|
| 1641 | 2 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18265380 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | ABBAS, SYED JARAR | 1674 | §102§103§112 | Non-Final OA | 44d overdue | Pending | Jun 05, 2023 |
| 18100885 | HUMANIZED ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF | DAHLE, CHUN WU | 1641 | Other | Final Rejection | 15d | Pending | Jan 24, 2023 |
| 17769180 | COMPOSITIONS AND METHODS FOR TREATING BLOOD DISORDERS | TAYLOR, LIA ELAN | 1641 | §103§112Other | Non-Final OA | — | Pending | Apr 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAnnexon, Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Syed Jarar Abbas has the most, with 1 of Annexon, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
